FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection #defendyourhealth #OrphanDrug #MarburgVirus https://lnkd.in/eRfBzKGr
Soligenix, Inc.
Biotechnology
Princeton, NJ 5,458 followers
We are a late-stage biopharmaceutical company focused on developing & commercializing products to treat rare diseases
About us
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and commercializing HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval and commercialization for this product is being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention / treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203). Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and vaccine programs targeting both filoviruses (such as Marburg and Ebola) and coronaviruses (COVID-19; CiVax™). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. We are also developing SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA).
- Website
-
http://www.soligenix.com
External link for Soligenix, Inc.
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Princeton, NJ
- Type
- Public Company
- Founded
- 1987
- Specialties
- biotechnology, oncology, rare disease, rare cancers, oral mucositis, Cutaneous T-Cell Lymphoma, ricin toxin vaccine, Pediatric Crohn’s disease, Head and neck cancer, Antibiotic resistant infectious disease, Photodynamic therapy, heat stable vaccines, Melioidosis, Hypericin, Ebola, Innate defense regulator, Infectious disease, Acute radiation enteritis, Ricin exposure, Acute radiation syndrome, Orphan diseases, and bioterrorism
Locations
-
Primary
29 Emmons Drive
Suite B-10
Princeton, NJ 08540, US
Employees at Soligenix, Inc.
Updates
-
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection #DefendYourHealth #OrphanDrug https://lnkd.in/d3CV-7GY
-
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency #defendyourhealth #clinicaltrials https://lnkd.in/e3yBUtaP
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
ir.soligenix.com
-
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results #defendyourhealth https://lnkd.in/eFSNQpqz
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
ir.soligenix.com
-
Celebrating all the amazing women in science, tech, engineering, and math who are pushing boundaries every day! #IWD2024 #InspireInclusion #internationalwomensday
-
Today we celebrate the women who are changing the world! #iwd2024 #inspireinclusion #internationalwomensday
-
Did you know rare diseases were so common, collectively? With more than 7,000 rare conditions, everyone likely knows someone impacted by a rare disease. This #RareDiseaseDay, learn about the vast yet diverse rare community: bit.ly/RDD2024 National Organization for Rare Disorders
-
There is so much progress yet to be made into researching treatments for rare diseases. This is a public health issue in every community. Learn what you can do to help on #RareDiseaseDay, February 29, the rarest day of the year: bit.ly/RDD2024 @NationalOrganizationforRareDisorders
-
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board. Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024. Read more: https://lnkd.in/e7Qha-nH
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
ir.soligenix.com